Logo wahanariau.com
  2. Junshi biosciences

Junshi biosciences

Index
Globenewswire

Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Kamis, 29 Oktober 2026 - 22:57:06 Wib
Globenewswire

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Kamis, 29 Oktober 2026 - 22:44:48 Wib
Globenewswire

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

Rabu, 28 Oktober 2026 - 22:07:33 Wib
Globenewswire

Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

Senin, 26 Oktober 2026 - 22:08:17 Wib
Globenewswire

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Kamis, 27 Agustus 2026 - 20:30:26 Wib
Globenewswire

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Rabu, 22 Juli 2026 - 20:30:57 Wib
Globenewswire

Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)

Kamis, 02 Juli 2026 - 22:48:29 Wib
Globenewswire

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Rabu, 27 Mei 2026 - 22:08:27 Wib
Globenewswire

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Kamis, 21 Mei 2026 - 22:23:08 Wib
Globenewswire

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Selasa, 21 April 2026 - 20:43:31 Wib
Globenewswire

Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates

Sabtu, 14 Maret 2026 - 02:59:57 Wib
Globenewswire

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

Selasa, 10 Maret 2026 - 06:18:29 Wib
Globenewswire

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

Rabu, 25 Februari 2026 - 21:17:42 Wib
Globenewswire

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Senin, 08 Desember 2025 - 21:43:47 Wib
Globenewswire

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Senin, 08 Desember 2025 - 21:42:57 Wib
Globenewswire

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Rabu, 26 November 2025 - 04:08:26 Wib
Globenewswire

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

Sabtu, 18 Oktober 2025 - 04:25:16 Wib
Globenewswire

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Senin, 08 September 2025 - 22:36:36 Wib
Globenewswire

Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

Rabu, 27 Agustus 2025 - 23:15:08 Wib
Globenewswire

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Sabtu, 09 Agustus 2025 - 00:56:21 Wib
Globenewswire

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

Selasa, 27 Mei 2025 - 19:30:00 Wib
Globenewswire

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Jumat, 25 April 2025 - 21:50:09 Wib
Globenewswire

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

Sabtu, 29 Maret 2025 - 22:23:41 Wib
Globenewswire

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Jumat, 28 Maret 2025 - 02:09:02 Wib
Globenewswire

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma

Senin, 24 Maret 2025 - 22:53:00 Wib